ArticleFrontiers in public health2024
The economic burden of atopic dermatitis in Romania: a broad perspective.
Article in Frontiers in public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Smartphone-Based Digital Eczema Education Program for Atopic Dermatitis in Children Aged 0 to 6 Years: Multicenter, Randomized, Parallel Controlled Clinical Study.Journal of medical Internet research · 2026Trial
- Special Issue "Diagnosis and Management of Skin Diseases, Related Disorders and Their Comorbidities".Diagnostics (Basel, Switzerland) · 2025Article
- Economic Burden of Alopecia Areata in the Kingdom of Saudi Arabia from a Societal Perspective: A Cost-of-Illness Analysis.Journal of health economics and outcomes research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Atopic dermatitis (AD), a common dermatological condition, is often associated with significant economic and social burdens. Despite extensive studies globally, there is a gap in understanding the impact of this condition in Romania. This study evaluated the economic burden of AD in Romania, considering both direct and indirect costs. Materials and methods: A cost of illness study, conducted from a broad perspective, considering 2022 as a reference, using top-down and bottom-up approaches and retrospective and prospective data sources was used to assess direct medical costs (treatments, medical services, hospitalizations), direct non-medical costs (associated costs due to transportation, accommodation), and indirect costs (productivity losses) across four costing scenarios. Results: In 2022, the total cost of atopic dermatitis in Romania was €29,810,077.2 for adult patients and €133,635,535.2 for pediatric patients, based on a prevalence-based approach, and €5,529,867.8 for adults and €53,175,049.1 for pediatric AD patients when using an incidence-based approach. Medical costs had the highest attributable share of the AD cost for adult patients while productivity costs (inquired by caregivers) had the highest share for pediatric AD patients in both approaches. The overall average annual cost per patient ranged, depending on the scenarios, between €284.72 and €1,045 for adult AD patients and between €293.73 and €9,558.52 for pediatric AD patients. Discussion: Our results show the increased burden among pediatric AD patients emphasizing the need that future policy interventions should be tailored according the patients' age.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.